

# Contents

|                                                                                             |            |
|---------------------------------------------------------------------------------------------|------------|
| <b>Author biographies</b>                                                                   | <b>vii</b> |
| <b>1 Introduction and background biology</b>                                                | <b>1</b>   |
| Introduction                                                                                | 1          |
| Epidemiology                                                                                | 1          |
| HER2 primary structure                                                                      | 2          |
| Signal transduction through receptor tyrosine kinases                                       | 4          |
| Receptor tyrosine kinases: site of therapeutic intervention                                 | 5          |
| Signaling through HER-receptor family dimers leads to the activation of downstream cascades | 5          |
| Conclusions                                                                                 | 10         |
| References                                                                                  | 10         |
| <b>2 HER2 testing</b>                                                                       | <b>13</b>  |
| Introduction                                                                                | 13         |
| Pre-analytic phase: sample handling                                                         | 14         |
| Analytic phase: HER2 testing methodologies                                                  | 15         |
| Post-analytic phase: screening and interpretation                                           | 17         |
| Alternate HER2 testing methodologies                                                        | 22         |
| References                                                                                  | 23         |
| <b>3 HER2-positive breast cancer: adjuvant and neoadjuvant therapy</b>                      | <b>25</b>  |
| Adjuvant setting                                                                            | 25         |
| Neoadjuvant therapy                                                                         | 33         |
| Current therapy standards for HER2-positive early breast cancer                             | 38         |
| Future directions and ongoing trials                                                        | 38         |
| References                                                                                  | 39         |
| <b>4 HER2-positive metastatic breast cancer: first-line treatment</b>                       | <b>43</b>  |
| Introduction                                                                                | 43         |

|                                                                            |           |
|----------------------------------------------------------------------------|-----------|
| Trastuzumab-based therapy                                                  | 43        |
| Pertuzumab                                                                 | 47        |
| Ongoing first-line studies                                                 | 51        |
| HER2/hormone receptor co-positive tumors                                   | 54        |
| Conclusions                                                                | 55        |
| References                                                                 | 56        |
| <b>5 HER2-positive metastatic breast cancer:<br/>second-line treatment</b> | <b>61</b> |
| Introduction                                                               | 61        |
| Trastuzumab emtansine                                                      | 62        |
| Lapatinib in the metastatic setting                                        | 68        |
| Investigations of trastuzumab-lapatinib combination therapy                | 70        |
| Conclusions                                                                | 70        |
| References                                                                 | 71        |
| <b>6 Emerging targeted agents for HER2-positive<br/>breast cancer</b>      | <b>75</b> |
| Challenges and unmet needs in HER2-positive breast cancer                  | 75        |
| Novel HER2 tyrosine kinase inhibitors                                      | 77        |
| PI3K/Akt/mTOR inhibition                                                   | 80        |
| Other signaling pathways                                                   | 85        |
| Boosting immunological response to HER2 blockade                           | 88        |
| Vascular endothelial growth factor inhibition                              | 90        |
| Conclusions                                                                | 91        |
| References                                                                 | 92        |

Handbook of HER2-targeted agents in breast cancer

Alvarez, R.H.; Cortés, J.; Mattos-Arruda, L.; Falzon, M.;

Fasolo, A.; Gandy, M.; Gianni, L.; Harbeck, N.; Piccart,

M.; Zambelli, S.; Zardavas, D.

2013, XI, 96 p. 13 illus., Softcover

ISBN: 978-1-907673-93-1